Proposal to list riluzole for the treatment of amyotrophic lateral sclerosis (motor neurone disease)

Medicines

Consultation Closed

PHARMAC is seeking feedback on a provisional agreement with Sanofi-Aventis to fund riluzole (Rilutek) for the treatment of amyotrophic lateral sclerosis (ALS, also known as motor neurone disease) from 1 October 2013 subject to the Special Authority and hospital access restrictions outlined on the following page.

Feedback sought

PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by 5 pm on Thursday 22 August 2013 to:

Geraldine MacGibbon
Senior Therapeutic Group Manager
PHARMAC

Email: geraldine.macgibbon@pharmac.govt.nz

Fax:     04 460 4995

Post:    PO Box 10 254, Wellington 6143

All feedback received before the closing date will be considered by PHARMAC’s Board (or its delegate) prior to making a decision on this proposal.